Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Database
Language
Document Type
Year range
1.
Biomolecules ; 12(7)2022 Jun 23.
Article in English | MEDLINE | ID: covidwho-1911171

ABSTRACT

The development of inexpensive, fast, and reliable screening tests for COVID-19 is, as yet, an unmet need. The present study was aimed at evaluating the usefulness of serum arylesterase activity of paraoxonase-1 (PON1) measurement as a screening test in patients with different severity levels of COVID-19 infection. We included 615 COVID-19-positive patients who were classified as asymptomatic, mildly symptomatic, severely symptomatic, or fatally symptomatic. Results were compared with 50 healthy volunteers, 330 patients with cancer, and 343 with morbid obesity. Results showed PON1 activity greatly decreased in COVID-19 compared to healthy volunteers; a receiver operating characteristics plot showed a high diagnostic accuracy. The degree of COVID-19 severity did not influence PON1 levels. Our results indicated that PON1 determination was efficient for disease diagnosis, but not for prognosis. Furthermore, patients with obesity or cancer presented alterations similar to those of COVID-19 patients. As such, elevated levels of PON1 indicate the absence of COVID-19, but low levels may be present in various other chronic diseases. The assay is fast and inexpensive. We suggest that PON1 measurement could be used as an initial, high cut-off point screening method, while lower values should be confirmed with the more expensive nucleic acid amplification test.


Subject(s)
Aryldialkylphosphatase , COVID-19 , Aryldialkylphosphatase/blood , COVID-19/blood , COVID-19/diagnosis , COVID-19/enzymology , Carboxylic Ester Hydrolases , Humans , Serum
2.
Front Immunol ; 12: 730710, 2021.
Article in English | MEDLINE | ID: covidwho-1441108

ABSTRACT

The COVID-19 pandemic caused by SARS-CoV-2 challenges the understanding of factors affecting disease progression and severity. The identification of prognostic biomarkers and physiological processes associated with disease symptoms is relevant for the development of new diagnostic and therapeutic interventions to contribute to the control of this pandemic. To address this challenge, in this study, we used a quantitative proteomics together with multiple data analysis algorithms to characterize serum protein profiles in five cohorts from healthy to SARS-CoV-2-infected recovered (hospital discharge), nonsevere (hospitalized), and severe [at the intensive care unit (ICU)] cases with increasing systemic inflammation in comparison with healthy individuals sampled prior to the COVID-19 pandemic. The results showed significantly dysregulated proteins and associated biological processes and disorders associated to COVID-19. These results corroborated previous findings in COVID-19 studies and highlighted how the representation of dysregulated serum proteins and associated BPs increases with COVID-19 disease symptomatology from asymptomatic to severe cases. The analysis was then focused on novel disease processes and biomarkers that were correlated with disease symptomatology. To contribute to translational medicine, results corroborated the predictive value of selected immune-related biomarkers for disease recovery [Selenoprotein P (SELENOP) and Serum paraoxonase/arylesterase 1 (PON1)], severity [Carboxypeptidase B2 (CBP2)], and symptomatology [Pregnancy zone protein (PZP)] using protein-specific ELISA tests. Our results contributed to the characterization of SARS-CoV-2-host molecular interactions with potential contributions to the monitoring and control of this pandemic by using immune-related biomarkers associated with disease symptomatology.


Subject(s)
COVID-19/blood , COVID-19/immunology , SARS-CoV-2 , Adult , Aged , Aged, 80 and over , Aryldialkylphosphatase/blood , Biomarkers/blood , Carboxypeptidase B2/blood , Female , Humans , Interleukin-1/blood , Interleukin-4/blood , Male , Middle Aged , Pregnancy Proteins/blood , Prognosis , Proteome/analysis , Proteomics , Retrospective Studies , Selenoprotein P/blood
3.
Sci Rep ; 11(1): 2291, 2021 01 27.
Article in English | MEDLINE | ID: covidwho-1065945

ABSTRACT

Coronavirus disease 2019 (COVID-19) pandemic is affecting millions of patients worldwide. The consequences of initial exposure to SARS-CoV-2 go beyond pulmonary damage, with a particular impact on lipid metabolism. Decreased levels in HDL-C were reported in COVID-19 patients. Since HDL particles display antioxidant, anti-inflammatory and potential anti-infectious properties, we aimed at characterizing HDL proteome and functionality during COVID-19 relative to healthy subjects. HDLs were isolated from plasma of 8 severe COVID-19 patients sampled at admission to intensive care unit (Day 1, D1) at D3 and D7, and from 16 sex- and age-matched healthy subjects. Proteomic analysis was performed by LC-MS/MS. The relative amounts of proteins identified in HDLs were compared between COVID-19 and controls. apolipoprotein A-I and paraoxonase 1 were confirmed by Western-blot analysis to be less abundant in COVID-19 versus controls, whereas serum amyloid A and alpha-1 antitrypsin were higher. HDLs from patients were less protective in endothelial cells stiumalted by TNFα (permeability, VE-cadherin disorganization and apoptosis). In these conditions, HDL inhibition of apoptosis was blunted in COVID-19 relative to controls. In conclusion, we show major changes in HDL proteome and decreased functionality in severe COVID-19 patients.


Subject(s)
COVID-19/blood , Lipoproteins, HDL/blood , Apolipoprotein A-I/blood , Aryldialkylphosphatase/analysis , Aryldialkylphosphatase/blood , COVID-19/epidemiology , COVID-19/pathology , COVID-19/virology , Case-Control Studies , Chromatography, Liquid/methods , Endothelial Cells/pathology , Female , France/epidemiology , Humans , Male , Middle Aged , Pandemics , Proteome/metabolism , Proteomics/methods , SARS-CoV-2/isolation & purification , Serum Amyloid A Protein/metabolism , Tandem Mass Spectrometry/methods , Tumor Necrosis Factor-alpha/blood , alpha 1-Antitrypsin/blood
SELECTION OF CITATIONS
SEARCH DETAIL